Evidence map›Paper›PMID 20522535›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2010

A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients.

Antonio Vukusich, Sonia Kunstmann, Cristian Varela, Daniela Gainza, Sebastian Bravo, Daniela Sepulveda, Gabriel Cavada, Luis Michea, Elisa T Marusic

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 10 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 10 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pharmacological interventions for asymptomatic carotid stenosis.The Cochrane database of systematic reviews · 2023 · on this map
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.Clinical journal of the American Society of Nephrology : CJASN · 2015
    Trial
  17. Trial
  18. Mineralocorticoid Receptor Antagonists in Dialysis.American journal of nephrology · 2026
    Review
  19. Review
  20. The Effect of Carotid Atherosclerosis on the Risk for Open-Angle Glaucoma.Investigative ophthalmology & visual science · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Antonio VukusichFaculty of Medicine, Universidad Los Andes, Santiago, Chile.
Sonia Kunstmann
Cristian Varela
Daniela Gainza
Sebastian Bravo
Daniela Sepulveda
Gabriel Cavada
Luis Michea
Elisa T Marusic
Universidad de Los Andes, Chile · CLClínica Dávila · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesHemodialysis patients (HD) display high rates of cardiac diseases and mortality. In chronic kidney disease, vascular injury leads to coronary artery disease, heart failure, and stroke. Carotid intima-media thickness (CIMT) measurements are currently widely used in randomized controlled trials (RCTs) to study the efficacy of interventions. An RCT was designed for the assessment of the safety and effectiveness of spironolactone to inhibit the progression of CIMT in HD patients as a primary outcome. Secondary outcomes included measurements of plasma potassium. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: HD patients were randomly assigned to receive 50 mg spironolactone or placebo thrice weekly after dialysis. In between dialysis sessions, plasma potassium concentrations were measured every month. Ultrasonographic measurements of CIMT were done at the beginning of the study and after 2 years.

resultsFifty-three age- and sex-adjusted patients (30 with drug and 23 with placebo) successfully completed the trial. There were no significant differences between the two groups in all profiles studied at baseline. Measurements of CIMT after 2 years showed a progression in the placebo group, whereas in the spironolactone group a significant decrease or even reversed CIMT was observed. Progression rates (mm/yr) were: common carotid, placebo: 0.06 +/- 0.07, spironolactone: 0.01 +/- 0.04; carotid bifurcation, placebo: 0.15 +/- 0.27, spironolactone: 0.0001 +/- 0.01; internal carotid, placebo: 0.10 +/- 0.12, spironolactone: -0.10 +/- 0.15. No episodes of hyperkalemia were observed, but a slight increase in plasma potassium was found in the spironolactone group.

conclusionsFifty milligrams of spironolactone thrice weekly significantly reduced the progression of CIMT in HD patients.

Indexed as

Renal DialysisAgedBiomarkersCarotid ArteriesCarotid Artery DiseasesChileDisease ProgressionDouble-Blind MethodFemaleHumansKidney Failure, ChronicMaleMiddle AgedMineralocorticoid Receptor AntagonistsPlacebo EffectPotassiumBiomarkersMineralocorticoid Receptor AntagonistsPotassiumSpironolactone

Identifiers

PMID20522535
PMCPMC2924413
OpenAlexW2119084971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.